Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
Journal of Clinical Oncology · 20.08.2024 · 42 (24) · 2860-2872
DOI: 10.1200/jco.24.00733 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.08.2024. Verfasst von Luis G Paz-Ares und 17 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Complutense University and Ciberonc, Madrid, Spain. Hauptthemen laut MEDLINE: Docetaxel, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 146-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS.
Abstract (Originalsprache)
PURPOSE The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non–small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti–PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported. METHODS Patients were randomly assigned 1:1 (stratified by histology, best response to last anti–PD-(L)1–containing regimen, and AGA treatment received or not) to SG (one 10 mg/kg intravenous infusion on days 1 and 8) or docetaxel (one 75 mg/m 2 intravenous infusion on day 1) in 21-day cycles. Primary end point was overall survival (OS). Key secondary end points were investigator-assessed progression-free survival (PFS), objective response rate, patient-reported symptom assessment, and safety. RESULTS In the intention-to-treat population (SG, n = 299; docetaxel, n = 304), 55.4% had one previous line of therapy. Median follow-up was 12.7 months (range, 6.0-24.0). The primary end point was not met. There was a numerical OS improvement for SG versus docetaxel (median, 11.1 v 9.8 months; hazard ratio [HR], 0.84 [95% CI, 0.68 to 1.04]; one-sided P = .0534), consistent across squamous and nonsquamous histologies. Median PFS was 4.1 versus 3.9 months (HR, 0.92 [95% CI, 0.77 to 1.11]). An OS benefit was observed for SG (n = 192) versus docetaxel (n = 191) in mNSCLC nonresponsive to last anti–PD-(L)1–containing regimen (3.5-month median OS increase; HR, 0.75 [95% CI, 0.58 to 0.97]); this was consistent across histologies. Among patients receiving SG and docetaxel, 6.8% and 14.2% discontinued because of treatment-related adverse events (TRAEs), respectively; 1.4% and 1.0%, respectively, had TRAEs leading to death. CONCLUSION Although statistical significance was not met, OS numerically improved with SG versus docetaxel, which was consistent across histologies. Clinically meaningful improvement in OS was noted in mNSCLC nonresponsive to last anti–PD-(L)1–containing regimen. SG was better tolerated than docetaxel and consistent with its known safety profile, with no new safety signals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Complutense University and Ciberonc, Madrid, Spain.
- Hospital Universitari i Politécnic La Fe de Valencia, Valencia, Spain.
- Henry Dunant Hospital Center, Athens, Greece.
- Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
- Asklepios Lung Clinic, German Center for Lung Research (DZL), Munich-Gauting, Germany.
- European Institute of Oncology IRCCS, Milan, Italy.
ORCID-Profile: Luis G Paz-Ares, Oscar Juan-Vidal, Giannis S Mountzios, Enriqueta Felip, Nicolas Girard, Takayuki Takahama, Scott P Owen, Firas B Badin, Irfan Cicin, Marina Chiara Garassino
Förderung
- NIMHD NIH HHS
Zitieren
APA
Paz-Ares, L. G., Juan-Vidal, O., Mountzios, G. S., Felip, E., Reinmuth, N., de Marinis, F., Girard, N., Patel, V. M., Takahama, T., Owen, S. P., Reznick, D. M., Badin, F. B., Cicin, I., Mekan, S., Patel, R., Zhang, E., Karumanchi, D., & Garassino, M. C. (2024). Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. Journal of Clinical Oncology, 42(24), 2860-2872. https://doi.org/10.1200/jco.24.00733
Vancouver
Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, et al. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. Journal of Clinical Oncology. 2024;42(24):2860-2872. doi:10.1200/jco.24.00733
BibTeX
@article{PazAres2024,
author = {Paz-Ares, Luis G and Juan-Vidal, Oscar and Mountzios, Giannis S and Felip, Enriqueta and Reinmuth, Niels and de Marinis, Filippo and Girard, Nicolas and Patel, Vipul M and Takahama, Takayuki and Owen, Scott P and Reznick, Douglas M and Badin, Firas B and Cicin, Irfan and Mekan, Sabeen and Patel, Riddhi and Zhang, Eric and Karumanchi, Divyadeep and Garassino, Marina Chiara},
title = {Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {24},
pages = {2860--2872},
doi = {10.1200/jco.24.00733}
}
EUVIMED